Alecensaro (alectinib)

pCPA File Number: 22922

Negotiation Status:

Under consideration for negotiation

Indication(s):

adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0350-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable